Loading: Yes
Auth User: None
Session: None
Direct Supabase User: None
Cookies: No Supabase cookies
healthspan.fund empowers a community to accelerate the translation of cutting-edge ageing research into real-world therapies, diagnostics, and devices. We turn donations of any amount - one-time or recurring - into vital, transparent capital for pioneering startups.
Bridging the gap between lab breakthroughs and accessible healthspan solutions requires focus and resources. healthspan.fund tackles this by combining open-source AI screening with crowd-reviewed evidence. Money, votes, and milestones are logged on a public ledger. Backers choose projects or diversify automatically—driving tangible impact through radical transparency.
Our mission: To democratise the translation of ageing science, making breakthroughs more accessible. We channel small, transparent monthly pledges into rigorously documented, AI-vetted ventures delivering concrete healthspan gains. Read our whitepaper for a detailed look at our approach.
Make donations of any amount - one-time or recurring monthly - to support cutting-edge longevity research in cellular reprogramming, senolytic compounds, and NAD+ metabolism.
Allocate manually or let our AI split your pledge across projects that match your interests in preventive medicine, biomarker research, and aging biology.
Track every transaction and milestone in real time on an immutable ledger, ensuring complete transparency in longevity funding.
Apply with a glass-box dossier—protocols, budgets, videos, regulatory letters.
Pass an open-source AI review scored on novelty, translational readiness and documentation quality.
Receive US $10,000–250,000 cheques and join a global community of testers, advisors, and champions.
Diversify across multiple, AI-vetted healthspan ventures with transparent tracking.
Comment directly on project data in our open dialogue system.
Track every milestone and transaction on an immutable ledger.
Milestones are concrete: regulatory filings, biomarker shifts, device approvals.
Progress is timestamped and independently verified before funds move to the next tranche.
Success stories recycle capital into the next wave, compounding grassroots contributions.
Founder, Chief Advisor
Founder of the 199 group of companies, advancing longevity through partial reprogramming and preventive medicine. Active investor and futurist shaping the future of human health and biotechnology.
Founding General Partner
Visionary thought leader at the intersection of longevity, innovation, and capital. Managing Partner at DEImpact with a decade of investment experience at Rockefeller Capital, UBS, and Man Group.
Founding General Partner
Experienced scientist and serial entrepreneur bridging longevity research with practical applications. Former COO/CEO of Gowing Life, President of Oxford Society for Ageing and Longevity.